{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:40:36Z","timestamp":1792856436342,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":1878,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["A11569"],"award-info":[{"award-number":["A11569"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AstraZeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1093\/annonc\/mdu363","type":"journal-article","created":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T04:56:34Z","timestamp":1406609794000},"page":"1988-1995","source":"Crossref","is-referenced-by-count":80,"title":["A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer"],"prefix":"10.1016","volume":"25","author":[{"given":"I.A.","family":"McNeish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.B.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Clamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Earl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Dawson-Athey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Persic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu363_bb0010","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu363_bb0015","first-page":"383","article-title":"A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients","volume":"23","author":"Kaern","year":"2002","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1093\/annonc\/mdu363_bb0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ijgc-00009577-200303000-00007","article-title":"Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer","volume":"13","author":"Ghamande","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdu363_bb0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4161\/cbt.12.4.16430","article-title":"Src family kinases and paclitaxel sensitivity","volume":"12","author":"Le","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mdu363_bb0030","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/cncr.22215","article-title":"The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors","volume":"107","author":"Alvarez","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu363_bb0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/gyno.2002.6851","article-title":"Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers","volume":"88","author":"Wiener","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdu363_bb0040","first-page":"2164","article-title":"Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model","volume":"5","author":"Wiener","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu363_bb0045","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cub.2004.06.049","article-title":"Microtubule dynamics are necessary for SRC family kinase-dependent growth cone steering","volume":"14","author":"Suter","year":"2004","journal-title":"Curr Biol"},{"key":"10.1093\/annonc\/mdu363_bb0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.bbrc.2003.08.012","article-title":"Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line","volume":"309","author":"Pengetnze","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1093\/annonc\/mdu363_bb0055","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1535-7163.217.4.2","article-title":"Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3","volume":"4","author":"Chen","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdu363_bb0060","doi-asserted-by":"crossref","first-page":"10381","DOI":"10.1158\/0008-5472.CAN-05-1822","article-title":"SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells","volume":"65","author":"George","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu363_bb0065","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.molonc.2009.01.002","article-title":"Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530","volume":"3","author":"Green","year":"2009","journal-title":"Mol Oncol"},{"key":"10.1093\/annonc\/mdu363_bb0070","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clbc.2011.03.021","article-title":"Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer","volume":"11","author":"Gucalp","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdu363_bb0075","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s10637-011-9650-4","article-title":"A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium","volume":"30","author":"Mackay","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdu363_bb0080","first-page":"249","article-title":"Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)","volume":"31","author":"Fury","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdu363_bb0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cllc.2013.08.001","article-title":"A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the Princess Margaret Hospital Phase II Consortium","volume":"15","author":"Laurie","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1093\/annonc\/mdu363_bb0090","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/CAD.0b013e328325a867","article-title":"A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study","volume":"20","author":"Lara","year":"2009","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdu363_bb0095","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/bjc.2012.158","article-title":"Phase I study of saracatinib (AZD0530) in combination with paclitaxel and\/or carboplatin in patients with solid tumours","volume":"106","author":"Kaye","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdu363_bb0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdu363_bb0105","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdu363_bb0110","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdr149","article-title":"Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)","volume":"23","author":"Lortholary","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu363_bb0115","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu363_bb0120","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1158\/1078-0432.CCR-10-0748","article-title":"Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors","volume":"16","author":"Baselga","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu363_bb0125","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bone.2011.12.017","article-title":"Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study","volume":"50","author":"Hannon","year":"2012","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdu363_bb0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2008.01.007","article-title":"Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer","volume":"109","author":"Linch","year":"2008","journal-title":"Gynecol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419366220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419366220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/10\/1988\/24064799\/mdu363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T15:16:55Z","timestamp":1689434215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419366220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0923753419366220"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu363","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}